The first drug, baricitinib, is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis. According to the WHO Guideline Development Group, it is strongly recommended for patients with severe or critical disease in combination with corticosteroids.
An employee works on the Production Line of a COVID-19 Vaccine in India
You need to Log in
and be a client to read this story in full and get access to audio and images.